Skip to main content
SpringerLink
Log in

Gynaecological Cancer in Older Adults with Frailty

  • Chapter
  • First Online:
Frailty in Older Adults with Cancer

  • 619 Accesses

Abstract

Gynaecological cancer consists of five individual subsites: ovarian, endometrial, cervical, vaginal and vulval cancer. The proportion of older patients with frailty diagnosed with the different types of gynaecological cancer varies but in all subsites the number of these patients is increasing. Older age and frailty influence both the investigation and management of gynaecological cancers. In common with many other cancers, specific evidence to guide treatment in older patients with frailty is limited. This chapter will cover all five subsites of gynaecological cancer and provide a review of the evidence available for their management from early to advanced stages. Where this evidence is lacking, a frailty specific approach is taken, highlighting the potential benefits and limitations of standard treatments. Advances in systemic therapy, surgery and radiotherapy, which may particularly improve outcomes for patients with frailty are highlighted. The need for shared decision-making is emphasised throughout.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wyrko Z. Frailty at the front door. Clin Med J R Coll Physicians London. 2015; https://doi.org/10.7861/clinmedicine.15-4-377.

  2. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. Journals Gerontol - Ser A Biol Sci Med Sci. 2001; https://doi.org/10.1093/gerona/56.3.m146.

  3. Rockwood K, Fox RA, Stolee P, Robertson D, Beattie BL. Frailty in elderly people: an evolving concept. CMAJ. 1994;150(4):489–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Sia TY, Wen T, Cham S, Friedman AM, Wright JD. Effect of frailty on postoperative readmissions and cost of care for ovarian cancer. Gynecol Oncol. 2020; https://doi.org/10.1016/j.ygyno.2020.08.024.

  5. Hay CM, Donovan HS, Campbell GB, Taylor SE, Wang L, Courtney-Brooks M. Chemotherapy in older adult gynecologic oncology patients: can a phenotypic frailty score predict tolerance? Gynecol Oncol. 2019; https://doi.org/10.1016/j.ygyno.2018.11.031.

  6. Kumar A, Langstraat CL, DeJong SR, McGree ME, Bakkum-Gamez JN, Weaver AL, LeBrasseur NK, Cliby WA. Functional not chronologic age: frailty index predicts outcomes in advanced ovarian cancer. Gynecol Oncol. 2017; https://doi.org/10.1016/j.ygyno.2017.07.126.

  7. Yao TT, DeJong SR, McGree ME, Weaver AL, Cliby WA, Kumar A. Frailty in ovarian cancer identified the need for increased postoperative care requirements following cytoreductive surgery. Gynecol Oncol. 2019; https://doi.org/10.1016/j.ygyno.2018.12.025.

  8. Narasimhulu DM, McGree ME, Weaver AL, Jatoi A, LeBrasseur NK, Glaser GE, Langstraat CL, Block MS, Kumar A. Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer. Gynecol Oncol. 2020;158:646–52.

    Article  CAS  Google Scholar 

  9. Soto-Perez-de-Celis E, Aapro M, Muss H. ASCO 2020: the geriatric assessment comes of age. Oncologist. JAMA 2018;319(18):1901–913. https://doi.org/10.1634/theoncologist.2020-0804.

  10. Mohile SG, Epstein RM, Hurria A, et al. Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community oncology research program. JAMA Oncol. 2020; https://doi.org/10.1001/jamaoncol.2019.4728.

  11. Soo W-K, King M, Pope A, Parente P, Darzins P, Davis ID. Integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy. J Clin Oncol. 2020; https://doi.org/10.1200/jco.2020.38.15_suppl.12011.

  12. Ovarian Cancer — Cancer Stat Facts.

    Google Scholar 

  13. Ovarian cancer incidence statistics | Cancer Research UK.

    Google Scholar 

  14. Fourcadier E, Trétarre B, Gras-Aygon C, Ecarnot F, Daurès JP, Bessaoud F. Under-treatment of elderly patients with ovarian cancer: a population based study. BMC Cancer. 2015; https://doi.org/10.1186/s12885-015-1947-9.

  15. Tortorella L, Vizzielli G, Fusco D, Cho WC, Bernabei R, Scambia G, Colloca G. Ovarian cancer management in the oldest old: improving outcomes and tailoring treatments. Aging Dis. 2017; https://doi.org/10.14336/AD.2017.0607.

  16. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019; https://doi.org/10.1016/S0140-6736(18)32552-2.

  17. National Comprehensive Cancer Network (2020) NCCN Clinical Practice Guidelines in Oncology: Ovarian cancer including fallopian tube and primary peritoneal cancer.

    Google Scholar 

  18. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; https://doi.org/10.1093/annonc/mdt333.

  19. Narasimhulu DM, McGree ME, Weaver AL, Jatoi A, LeBrasseur NK, Glaser GE, Langstraat CL, Block MS, Kumar A. Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer. Gynecol Oncol. 2020; https://doi.org/10.1016/j.ygyno.2020.05.046.

  20. Walter LC, Chair V, Baumgartner J, et al (2020) Continue NCCN Guidelines version 1.2020 older adult oncology.

    Google Scholar 

  21. Wildiers H, Heeren P, Puts M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014; https://doi.org/10.1200/JCO.2013.54.8347.

  22. Falandry C, Weber B, Savoye AM, et al. Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. Ann Oncol. 2013; https://doi.org/10.1093/annonc/mdt360.

  23. Tinquaut F, Freyer G, Pommeret F, et al. Validation of the geriatric vulnerability score (GVS) in older ovarian cancer (oOC) patients: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study. Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz250.005.

  24. Joueidi Y, Dion L, Bendifallah S, et al. Management and survival of elderly and very elderly patients with ovarian cancer: an age-stratified study of 1123 women from the FRANCOGYN group. J Clin Med. 2020;9:1451.

    Article  Google Scholar 

  25. Cloven NG, Manetta A, Berman ML, Kohler MF, DiSaia PJ. Management of ovarian cancer in patients older than 80 years of age. Gynecol Oncol. 1999; https://doi.org/10.1006/gyno.1998.5337.

  26. Wright JD, Herzog TJ, Powell MA. Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol. 2004; https://doi.org/10.1016/j.ajog.2004.01.078.

  27. Fanfani F, Fagotti A, Salerno MG, Margariti PA, Gagliardi ML, Gallotta V, Vizzielli G, Panico G, Monterossi G, Scambia G. Elderly and very elderly advanced ovarian cancer patients: does the age influence the surgical management? Eur J Surg Oncol. 2012; https://doi.org/10.1016/j.ejso.2012.08.003.

  28. Filippova OT, Chi DS, Long Roche K, et al. Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center. Gynecol Oncol. 2019; https://doi.org/10.1016/j.ygyno.2019.04.683.

  29. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; https://doi.org/10.1056/NEJMoa0908806.

  30. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; https://doi.org/10.1016/S0140-6736(14)62223-6.

  31. Onda T, Satoh T, et al. Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602. J Clin Oncol. 2018; https://doi.org/10.1200/jco.2018.36.15_suppl.5500.

  32. Parmar MKB, Adams M, Balestrino M, et al. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002; https://doi.org/10.1016/S0140-6736(02)09738-6.

  33. Falandry C, Savoye AM, Stefani L, et al. EWOC-1: a randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): a GCIG-ENGOT-GINECO study. J Clin Oncol. 2019;37:5508.

    Article  Google Scholar 

  34. Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014; https://doi.org/10.1016/S1470-2045(14)70049-X.

  35. Pignata S, Ferrandina G, Scarfone G, et al. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. Crit Rev Oncol Hematol. 2009; https://doi.org/10.1016/j.critrevonc.2008.12.010.

  36. Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012; https://doi.org/10.1038/bjc.2012.307.

  37. Tew WP, Lichtman SM. Ovarian cancer in older women. Semin Oncol. 2008; https://doi.org/10.1053/j.seminoncol.2008.08.007.

  38. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; https://doi.org/10.1056/NEJMoa1104390.

  39. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; https://doi.org/10.1056/NEJMoa1103799.

  40. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012; https://doi.org/10.1200/JCO.2012.42.0505.

  41. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; https://doi.org/10.1200/JCO.2013.51.4489.

  42. Selle F, Colombo N, Korach J, Mendiola C, Cardona A, Ghazi Y, Oza AM. Safety and efficacy of extended bevacizumab therapy in elderly (≥70 years) versus younger patients treated for newly diagnosed ovarian cancer in the international ROSiA study. Int J Gynecol Cancer. 2018; https://doi.org/10.1097/IGC.0000000000001221.

  43. Mustea A, Wimberger P, Oskay-Oezcelik G, et al. Impact of age on the safety and efficacy of bevacizumab (BEV)-containing therapy in patients (pts) with primary ovarian cancer (OC): analyses of the OTILIA German non-interventional study on behalf of the north-eastern German Society of Gynaecological Onc. Ann Oncol. 2016;27:vi299.

    Article  Google Scholar 

  44. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; https://doi.org/10.1056/NEJMoa1105535.

  45. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; https://doi.org/10.1016/S1470-2045(17)30469-2.

  46. Fields EC, McGuire WP, Lin L, Temkin SM. Radiation treatment in women with ovarian cancer: past, present, and future. Front Oncol. 2017;7:177.

    Article  Google Scholar 

  47. Lewin SN, Buttin BM, Powell MA, Gibb RK, Rader JS, Mutch DG, Herzog TJ. Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol. 2005; https://doi.org/10.1016/j.ygyno.2005.07.102.

  48. Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA - J Am Med Assoc. 2008; https://doi.org/10.1001/jama.300.14.1665.

  49. Rustin GJS, Van Der Burg MEL, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010; https://doi.org/10.1016/S0140-6736(10)61268-8.

  50. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; https://doi.org/10.3322/caac.21492.

  51. Soisson S, Ganz PA, Gaffney D, et al. Long-term cardiovascular outcomes among endometrial cancer survivors in a large, population-based cohort study. J Natl Cancer Inst. 2018; https://doi.org/10.1093/jnci/djy070.

  52. Office for National Statistics (2019) Cancer survival in England: adult, stage at diagnosis and childhood - patients followed up to 2018. Off. Natl. Stat.

    Google Scholar 

  53. Lachance JA, Everett EN, Greer B, Mandel L, Swisher E, Tamimi H, Goff B. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2006;101:470–5.

    Article  CAS  Google Scholar 

  54. Clark LH, Jackson AL, Gehrig PA, Bae-Jump V, Van Le L, Ko EM. Adjuvant treatment and clinical trials in elderly patients with endometrial cancer: a time for change? Int J Gynecol Cancer. 2016; https://doi.org/10.1097/IGC.0000000000000605.

  55. Driver JA, Viswanathan AN. Frailty measure is more predictive of outcomes after curative therapy for endometrial cancer than traditional risk factors in women 60 and older. Gynecol Oncol. 2017; https://doi.org/10.1016/j.ygyno.2017.03.010.

  56. NICE Guidelines (2017) Suspected cancer: recognition and referral | guidance and guidelines | NICE. In: NICE Guid.

    Google Scholar 

  57. Ciatto S, Cecchini S, Gervasi G, Landini A, Zappa M, Crocetti E. Association of endometrial thickness assessed at transvaginal ultrasonography to endometrial cancer in postmenopausal women asymptomatic or with abnormal uterine bleeding. Radiol Med. 2002;104(5-6):437–42.

    PubMed  Google Scholar 

  58. Wright JD, Lewin SN, Barrena Medel NI, Sun X, Burke WM, Deutsch I, Herzog TJ. Endometrial cancer in the oldest old: tumor characteristics, patterns of care, and outcome. Gynecol Oncol. 2011; https://doi.org/10.1016/j.ygyno.2011.02.040.

  59. Ahmed A, Zamba G, DeGeest K, Lynch CF. The impact of surgery on survival of elderly women with endometrial cancer in the SEER program from 1992-2002. Gynecol Oncol. 2008; https://doi.org/10.1016/j.ygyno.2008.06.026.

  60. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016; https://doi.org/10.1093/annonc/mdv484.

  61. Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2017; https://doi.org/10.1002/14651858.CD007585.pub4.

  62. Rudolph JL, Marcantonio ER. Postoperative delirium: acute change with long-term implications. Anesth Analg. 2011; https://doi.org/10.1213/ANE.0b013e3182147f6d.

  63. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, Spiegel G, Barakat R, Pearl ML, Sharma SK. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: gynecologic oncology group study LAP2. J Clin Oncol. 2009; https://doi.org/10.1200/JCO.2009.22.3248.

  64. Rupp-Montpetit K, Moody ML. Visual loss as a complication of non-ophthalmologic surgery: a review of the literature. AANA J. 2004;72:285–92.

    PubMed  Google Scholar 

  65. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev. 2012; https://doi.org/10.1002/14651858.CD003916.pub4.

  66. Nout RA, Smit VTHBM, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet (London, England). 2010;375:816–23.

    Article  CAS  Google Scholar 

  67. Francis SR, Ager BJ, Do OA, Huang Y-HJ, Soisson AP, Dodson MK, Werner TL, Sause WT, Grant JD, Gaffney DK. Recurrent early stage endometrial cancer: patterns of recurrence and results of salvage therapy. Gynecol Oncol. 2019;154:38–44.

    Article  Google Scholar 

  68. van der Steen-Banasik E, Christiaens M, Shash E, Coens C, Casado A, Herrera FG, Ottevanger PB. Systemic review: radiation therapy alone in medical non-operable endometrial carcinoma. Eur J Cancer. 2016;65:172–81.

    Article  Google Scholar 

  69. Johnson N, Bryant A, Miles T, Hogberg T, Cornes P. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev. 2011; https://doi.org/10.1002/14651858.CD003175.pub2.

  70. de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:295–309.

    Article  Google Scholar 

  71. Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2010; https://doi.org/10.1002/14651858.CD007926.pub2.

  72. Coleridge S, Morrison J. Patient-initiated follow-up after treatment for low risk endometrial cancer: a prospective audit of outcomes and cost benefits. Int J Gynecol Cancer. 2020;30:1177–82.

    Article  Google Scholar 

  73. Seamon LG, Java JJ, Monk BJ, et al. Impact of tumour histology on survival in advanced cervical carcinoma: an NRG oncology/Gynaecologic oncology group study. Br J Cancer. 2018;118:162–70.

    Article  Google Scholar 

  74. World Health Organisation (2014) Comprehensive cervical cancer control. WHO Libr Cat Data, p 364.

    Google Scholar 

  75. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393:169–82.

    Article  Google Scholar 

  76. Kissel M, Rambeau A, Achkar S, Lecuru F, Mathevet P. Challenges and advances in cervix cancer treatment in elder women. Cancer Treat Rev. 2020;84:101976.

    Article  CAS  Google Scholar 

  77. Darlin L, Borgfeldt C, Widén E, Kannisto P. Elderly women above screening age diagnosed with cervical cancer have a worse prognosis. Anticancer Res. 2014;

    Google Scholar 

  78. Kang Y, Smith M, Barlow E, Coffey K, Hacker N, Canfell K. Vulvar cancer in high-income countries: increasing burden of disease. Int J Cancer. 2017;141:2174–86.

    Article  CAS  Google Scholar 

  79. Gilbert DC, Wakeham K, Langley RE, Vale CL. Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis. Br J Cancer. 2019;120:256–68.

    Article  Google Scholar 

  80. Wiggans A, Coleridge S, Bryant A, Morrison J. Relationship between vulvar symptoms and incidence of vulvar cancer in women referred to a rapid access clinic. Int J Gynecol Obstet. 2019;145:283–6.

    Article  CAS  Google Scholar 

  81. Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018;379:1895–904.

    Article  Google Scholar 

  82. Nama V, Angelopoulos G, Twigg J, Murdoch JB, Bailey J, Lawrie TA. Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage IB2 cervical cancer. Cochrane Database Syst Rev. 2018; https://doi.org/10.1002/14651858.CD011478.pub2.

  83. Yan R, Zeng Z, Liu F, Zeng Y, He T, Xiang Z, Zhang B, Gong H, Liu L. Primary radical hysterectomy vs chemoradiation for IB2-IIA cervical cancer. Medicine (Baltimore). 2020;99:e18738.

    Article  Google Scholar 

  84. Te Grootenhuis NC, Van Der Zee AGJ, Van Doorn HC, et al. Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational study on sentinel nodes in vulvar cancer (GROINSS-V) i. Gynecol Oncol. 2016; https://doi.org/10.1016/j.ygyno.2015.09.077.

  85. Morrison J, Baldwin P, Buckley L, et al. British Gynaecological cancer society (BGCS) vulval cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 2020;252:502–25.

    Article  Google Scholar 

  86. Zhou W, Yue Y, Pei D. Survival benefit of vaginectomy compared to local tumor excision in women with FIGO stage I and II primary vaginal carcinoma: a SEER study. Arch Gynecol Obstet. 2020; https://doi.org/10.1007/s00404-020-05737-6.

  87. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynecol Obstet. 2018;143:22–36.

    Article  Google Scholar 

  88. Vale C. Reducing uncertainties about the effects of Chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26:5802–12.

    Article  CAS  Google Scholar 

  89. Hata M, Koike I, Kasuya T, Kaizu H, Matsui T, Inoue T, Miyagi E, Numazaki R, Asai-Sato M, Hirahara F. Radiation therapy for very elderly patients aged 80 years and older with squamous cell carcinoma of the uterine cervix. Am J Clin Oncol Cancer Clin Trials. 2017;40:178–82.

    Google Scholar 

  90. Nakamura R, Shimoji Y, Nakasone T, Taira Y, Arakaki Y, Nakamoto T, Ooyama T, Kudaka W, Mekaru K, Aoki Y. Relative dose intensity and overall treatment time in older patients with cervical cancer treated with concurrent chemoradiotherapy. J Geriatr Oncol. 2020;62:20–2.

    Google Scholar 

  91. Tanderup K, Eifel PJ, Yashar CM, Pötter R, Grigsby PW. Curative radiation therapy for locally advanced cervical cancer: brachytherapy is NOT optional. Int J Radiat Oncol Biol Phys. 2014;88:537–9.

    Article  Google Scholar 

  92. Van Lonkhuijzen L, Thomas G. Palliative radiotherapy for cervical carcinoma, a systematic review. Radiother Oncol. 2011;98:287–91.

    Article  Google Scholar 

  93. Tewari KS, DiSaia PJ, Sill MW, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (gynecologic oncology group 240). Lancet. 2017;390:1654–63.

    Article  CAS  Google Scholar 

  94. Kirchheiner K, Pötter R, Nout RA, Schwartz-Vittrup A, Holzner B, Bentzen SM, Tanderup K. Late, persistent, substantial, treatment-related symptoms after radiation therapy (LAPERS): a new method for longitudinal analysis of late morbidity—applied in the EMBRACE study. Int J Radiat Oncol Biol Phys. 2020; https://doi.org/10.1016/j.ijrobp.2019.10.027.

  95. Gibson W, Johnson T, Kirschner-Hermanns R, Kuchel G, Markland A, Orme S, Ostaszkiewicz J, Szonyi G, Wyman J, Wagg A. Incontinence in frail elderly persons: report of the 6th international consultation on incontinence. Neurourol Urodyn. 2020;40(1):38–54.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Border Medical Oncology, Albury Wodonga Regional Cancer Centre, Albury, Australia

    Christopher Steer & Bridget Josephs

  2. University of NSW, Rural Clinical School, Albury Campus, Albury, NSW, Australia

    Christopher Steer

  3. Clinical Oncology Department, Clatterbridge Cancer Centre, Liverpool, UK

    Anthea Cree

  4. Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

    Y. Louise Wan

Authors
  1. Christopher Steer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bridget Josephs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthea Cree
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. Louise Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher Steer .

Editor information

Editors and Affiliations

  1. Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK

    Fabio Gomes

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Steer, C., Josephs, B., Cree, A., Wan, Y.L. (2022). Gynaecological Cancer in Older Adults with Frailty. In: Gomes, F. (eds) Frailty in Older Adults with Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-89162-6_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-89162-6_25

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-89161-9

  • Online ISBN: 978-3-030-89162-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation